ReviewCancerPublished
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer
Regional connection
Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source
- Institutions
- Fox Chase Cancer Center, Temple Health
- County
- Philadelphia County
Publication record
- Type
- Review
- Venue
- Cancer
- Published
- Topic
- Clinical care
- Subject terms
- T-Lymphocytes; Humans; Lung Neoplasms; Membrane Proteins; Antibodies, Bispecific; Immunotherapy; Small Cell Lung Carcinoma; Cytokine Release Syndrome; Safety Profile; Adverse Event Management; Tarlatamab; Dellphi‐301
- PubMed ID
- 39876075
- PubMed Central ID
- PMC11775405
- Open access
- Yes, open
- Added to directory
- Source checked